Individualised Prophylaxis

No two days are the same. No two patients are the same. Find out more about individualised prophylaxis for real life.

Find out more

Confidence in Haemophilia Care

The Confidence in Haemophilia Care meeting brought together an expert faculty to explore contemporary topics in haemophilia management – including inhibitor development, pharmacokinetic and assay considerations in haemophilia care, and much more.

View videos

Patient materials

Access materials to support your haemophilia patients.

View materials

What is haemophilia?

Haemophilia is a lifelong condition requiring constant and careful management. The most common forms of haemophillia are caused by deficiency in a particular coagulation factor – factor VIII (FVIII) in haemophilia A and factor IX (FIX) in haemophilia B.

Haemophilia is quite rare; about 1 in 10,000 people are born with it1.

Treatment of haemophilia

A primary aim of care in haemophilia is to prevent and treat bleeding with the deficient clotting factor2:

  • On-demand: Treatment given at the time of clinically evident bleeding
  • Prophylaxis: Treatment given in order to prevent anticipated bleeding

Pfizer in haemophilia

Pfizer helps to find practical approaches to haemophilia care through partnering with various organisations. Through scientific collaboration and long-term investment in new haemophilia therapies, we aim to advance the treatment and address the unmet needs of people with haemophilia.

Pfizer has partnered with various organisations to help find practical approaches to haemophilia care

  • Pfizer is committed to the improvement of long-term outcomes for people with haemophilia and the support they receive to manage their conditions
  • Through scientific collaboration and long-term investment in new haemophilia therapies, we aim to advance the treatment and address the unmet needs of people with haemophilia

Milestones in Pfizer Haemophilia

Pfizer continues to invest in the research and development of haemophilia treatment3 – the key time points for this are outlined in the figure below.

* Pfizer acquired Wyeth on 15 October 2009.14
References: 1. World Federation of Hemophilia. What is Hemophilia? Available at: http://www1.wfh.org/publications/files/pdf-1324.pdf (accessed January 2017). 2.World Federation of Hemophilia. Guidelines for the Management of Hemophilia–2nd Edition. Available at: http://www1.wfh.org/publications/files/pdf-1472.pdf (accessed January 2017). 3. Kelley B et al. An improved manufacturing process for Xyntha/
ReFactoAF. Haemophilia 2010;16(5):717–725. 4. Funding Universe. Genetics Institute, Inchistory. Available at: http://www.fundinguniverse.com/company-histories/genetics-institute-inc-...(accessed January 2017). 5. CenterWatch. BeneFIX(coagulation Factor IX (recombinant)). Available at: http://www.centerwatch.com/drug-information/fda-approved-drugs/drug/229/...(accessed January 2017). 6. ReFactoAF® moroctocogalfa(recombinant coagulation factor VIII) Summary of Product Characteristics. Available at: http://www.ema.europa.eu/ema/(accessed January 2017). 7. BioSpace. Wyeth Receives FDA Approval for New BeneFIX Features That Provide Hemophilia B Patients a Simpler and More Convenient Preparation Process for Recombinant Factor IX, published 26th March 2007. Available at: https://www.biospace.com/article/releases/wyeth-receives-fda-approval-for-new-benefix-features-that-provide-hemophilia-b-patients-a-simpler-and-more-convenient-preparation-process-for-recombin/ (accessed November 2018). 8. Lambert T et al. Reformulated BeneFIX: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B. Haemophilia 2007;13(3):233–243. 9. European Medicines Agency. Assessment report for ReFacto® AF. 2009. Doc ref: EMEA/55167/2009. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_R...(accessed January 2017). 10. BeneFIX® (nonacogalfa) Summary of Product Characteristics. Available at: http://www.ema.europa.eu/ema/(accessed January 2017). 11. European Medicines Agency. BeneFIXEPAR –procedural steps taken and scientific information after the authorisation. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Procedural_s...(accessed January 2017). 12. European Medicines Agency. BeneFIXassessment report. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_R...(accessed January 2017). 13. Pfizer.co.uk. The Rare Disease Consortium. Available at: https://www.pfizer.co.uk/rare-disease-consortium (accessed March 2018). 14. Business Wire. Pfizer completes acquisition of Wyeth. Available at: http://www.businesswire.com/news/home/20091015005867/en/Pfizer-Completes...(accessed January 2017).

 

PP-BEN-GBR-0241. November 2018

Click here for BeneFIX® prescribing information.
Click here for ReFacto AF® prescribing information.